Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) et al.   European Journal of Preventive Cardiology

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

(2015) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?

(2015) Amit V Khera et al.   European Journal of Preventive Cardiology

Discontinuation of Statins in Routine Care Settings

(2013) Huabing Zhang et al.   ANNALS OF INTERNAL MEDICINE

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

(2013) David C. Goff et al.   CIRCULATION

Lipoprotein apheresis: an update

(2013) Ulrich Julius et al.   Clinical Lipidology

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

(2012) et al.   EUROPEAN HEART JOURNAL

Discontinuation of statin therapy due to muscular side effects: A survey in real life

(2012) D. Rosenbaum et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET